ICN Reinforces Its Presence In Russia

4 May 1997

The European base of US drug group ICN Pharmaceuticals has been switchedfrom Belgrade (former Yugoslavia) to Moscow, Russia. The new headquarters has been inaugurated by ICN president Milan Panic.

ICN has been on the Russian drug market for three years, and is now the only foreign drugmaker to be involved in both developing local production and marketing its products. The firm has acquired three plants in St Petersburg, Kursk and Chelyabinsk, with investment of $100 million; modernization projects are underway at all three companies. Mr Panic said Russia "is to remain a priority market," and all profits made there will be reinvested.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight